- Home
- PCSC vs LCTX Comparison
PCSC vs LCTX Comparison
Compare PCSC & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCSC
- LCTX
- Stock Information
- Founded
- PCSC 2024
- LCTX 1990
- Country
- PCSC United States
- LCTX United States
- Employees
- PCSC N/A
- LCTX N/A
- Industry
- PCSC
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PCSC
- LCTX Health Care
- Exchange
- PCSC NYSE
- LCTX Nasdaq
- Market Cap
- PCSC 114.2M
- LCTX 107.3M
- IPO Year
- PCSC 2024
- LCTX N/A
- Fundamental
- Price
- PCSC $10.54
- LCTX $0.66
- Analyst Decision
- PCSC
- LCTX Strong Buy
- Analyst Count
- PCSC 0
- LCTX 5
- Target Price
- PCSC N/A
- LCTX $4.20
- AVG Volume (30 Days)
- PCSC 549.0
- LCTX 1.1M
- Earning Date
- PCSC 01-01-0001
- LCTX 05-13-2025
- Dividend Yield
- PCSC N/A
- LCTX N/A
- EPS Growth
- PCSC N/A
- LCTX N/A
- EPS
- PCSC N/A
- LCTX N/A
- Revenue
- PCSC N/A
- LCTX $9,557,000.00
- Revenue This Year
- PCSC N/A
- LCTX N/A
- Revenue Next Year
- PCSC N/A
- LCTX $232.66
- P/E Ratio
- PCSC $45.93
- LCTX N/A
- Revenue Growth
- PCSC N/A
- LCTX 19.42
- 52 Week Low
- PCSC $10.02
- LCTX $0.37
- 52 Week High
- PCSC $10.57
- LCTX $1.15
- Technical
- Relative Strength Index (RSI)
- PCSC N/A
- LCTX 66.01
- Support Level
- PCSC N/A
- LCTX $0.48
- Resistance Level
- PCSC N/A
- LCTX $0.70
- Average True Range (ATR)
- PCSC 0.00
- LCTX 0.05
- MACD
- PCSC 0.00
- LCTX 0.02
- Stochastic Oscillator
- PCSC 0.00
- LCTX 69.26
About PCSC PERCEPTIVE CAP SOLUTIONS CORP
Perceptive Capital Solutions Corp is a blank check company.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.